Composition for preventing and/or treating renal injury and renal failure

A composition and a technique for renal failure, applied in the field of medicine, can solve problems such as the treatment and prevention of renal function diseases that have not been seen in its application

Inactive Publication Date: 2018-11-02
MUDANJIANG YOUBO PHARMA CO LTD
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the natural MG53 protein is mainly limited to skeletal muscle and myocardial tissue, exogenous MG53 protein also has biological activity and performs its repair function, but it has not been used in the treatment and prevention of renal diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing and/or treating renal injury and renal failure
  • Composition for preventing and/or treating renal injury and renal failure
  • Composition for preventing and/or treating renal injury and renal failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Preparation of lyophilized formulations

[0037] Active ingredient: Utilize conventional gene recombination technology to produce recombinant MG53 protein, the method is as follows:

[0038] Firstly, total RNA (total RNA) was extracted from human skeletal muscle or cardiac tissue, and then a part of PCR amplification was performed with specific primers of MG53, and then the PCR product was directly purified and sequenced. After the sequence was confirmed to be correct, the fragment was combined with eukaryotic In the expression vector pcDNA4 / V5-His A, the vector was transformed into the 293T cell line with a transfection reagent, and then the stable expression cell line (293T-MG53) was screened using the Zeocin selection marker. Expand and cultivate the cell line, and then undergo separation and purification steps such as affinity chromatography and ion exchange chromatography to obtain MG53 protein with a purity of more than 95%. The N-terminal sequence of the protein ...

Embodiment 2

[0042] Effects of MG3 protein mutants on mouse models of acute kidney injury

[0043] Objective: To study the effect of MG53 protein mutants using a mouse model of acute kidney injury

[0044] Materials and methods: BALB / c mice, male, weighing 18-22g, were randomly divided into normal control group, model control group, low-dose group (0.5mg / kg), middle-dose group (2mg / kg), high-dose group Dose group (5mg / kg), 15 rats in each group.

[0045] The experimental group was intragastrically administered a corresponding amount of the composition, and the normal control group and the model control group were intravenously injected with corresponding volumes of normal saline. Once a day, continuous administration for 7 days. After the last administration, except the normal control group, the other groups were intraperitoneally injected endotoxin at 50 mg / kg to establish the endotoxin-acute kidney injury model, and the normal control group was injected with the same dose of normal sal...

Embodiment 3

[0079] Effects of MG3 protein mutants on nephrectomy-induced chronic renal failure in rats

[0080] Objective: To study the effect of MG53 protein mutants on chronic renal failure in rats

[0081] Materials and methods: 120 rats, weighing 150-200g, fed the animals for 1 week, divided the animals into 6 groups, 20 rats in each group, namely the normal group, the model group, and the glutathione intravenous injection (150mg / kg) group , MG53 mutant low-dose group, MG53 mutant medium-dose group, MG53 mutant high-dose group, in addition to the normal group, rats were made into chronic renal failure models by 5 / 6 nephrectomy,

[0082] 2 / 3 of the left kidney was resected in the first operation, and the right kidney was resected in the second operation one week later. Drugs were started 5 weeks after the second operation. The MG53 mutant was administered by tail vein injection. Blood was collected from the eye sockets of the rats at 1 week and 8 weeks respectively, and serum creatini...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a composition for preventing and/or treating renal injury and renal failure. The composition is prepared from one or more of MG53 protein and a MG53 protein mutant, wherein theMG53 protein mutant is a structure that a serine site in a Coiled-coil structural domain of the MG53 protein is mutated as alanine, specifically one or more of MG53 S150A, MG 53 S189A, MG53 S211A. The invention further discloses a composition for preventing and/or treating renal injury and renal failure. The composition containing the MG53 protein and/or the mutant thereof utilizes recombinant human MG53 protein to prove that the MG53 has obvious preventing and/or treating effect for chronic ulcer in a drug for preventing and/or treating renal injury and renal failure, and is of greater meaning in clinical application in developing a drug for treating renal injury and renal failure.

Description

technical field [0001] The invention relates to the field of medicine, and relates to a composition for preventing and / or treating renal damage and renal failure. Background technique [0002] Acute kidney injury (AKI) or acute renal failure (ARF) is caused by various reasons such as infection, burn, trauma, renal artery stenosis and shock, among which sepsis is one of the most important clinical causes of acute kidney injury. It is a common clinical critical disease with acute onset, rapid course of disease, high mortality and case fatality rate, and the incidence rate is increasing year by year. Exacerbation of ARF has been reported to result in hospitalization in approximately 5%, cardiopulmonary bypass surgery in 4–15%, and intensive care in as many as 30%. Generally speaking, the fatality rate of acute kidney injury is 45%, but the fatality rate can rise to 70% after sepsis, which has become one of the major problems in critical care and emergency medicine. [0003] C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K45/06A61P13/12
CPCA61K38/1709A61K45/06A61P13/12
Inventor 慎东
Owner MUDANJIANG YOUBO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap